Addressing challenges of Alzheimer's value
and diagnostic value assessment in Europe
ABOUT PAVE
-
22
Members and Advisors
-
10
Countries
Our Partners and Sponsors
Who Is Involved
Clinicians
Patient Advocates
Health Economists
HTA & Regulatory Experts
Industry
What People Are Saying
“Scientific progress on Alzheimer's has drastically improved our understanding of the disease — but connecting new innovations to the patients who need them most remains the critical challenge. Earlier diagnosis and treatment are key, and health systems must keep pace with the science if we are to deliver on the promise of a better future for people living with this disease and their loved ones.”
Laura Campo
Executive Director, Global Corporate Affairs,
Alzheimer's disease, Eli Lilly
“Early detection and timely diagnosis will be key to unlocking access to future disease-modifying therapies.”
Lydia Lanman, Global
Policy Director, F. Hoffmann-La Roche
“HTA bodies need to better understand the holistic impact of Alzheimer’s disease on families and societies. Evidence to support this is there, but requires that frameworks for value assessment must be reconsidered.””
Annie Chicoye,
Health Economist,
Sciences Po Paris